Twist Bioscience Corporation (TWST) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in South San Francisco, CA, United States. The current CEO is Emily Marine Leproust.
TWST has IPO date of 2018-10-31, 923 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.52B.
Twist Bioscience Corporation is a synthetic biology company that manufactures and sells synthetic DNA-based products using its proprietary DNA synthesis platform, which writes DNA directly onto silicon chips. The company offers a diverse portfolio including synthetic genes, sample preparation tools, antibody libraries for drug discovery, and DNA-based digital data storage solutions. Twist has established strategic collaborations with leading pharmaceutical and biotechnology firms such as Boehringer Ingelheim, Kyowa Kirin, and Centogene to advance sequencing tools and therapeutic antibody discovery. Founded in 2013 and headquartered in South San Francisco, California, the company serves the pharmaceutical, diagnostics, and data storage industries.
